glp-1 controversy Hims & Hers, and the Brewing Compounding Glucagon-like peptide-1 receptor: mechanisms and

Description

The $10 billion price tag, the bidding war with Novo Nordisk, the lawsuits, it all made for high drama

Typical replacement times vary

Here we review published data from 24-h time-averaged HR monitoring in healthy individuals and subjects with type 2 diabetes mellitus (T2DM) treated with either short-acting GLP-1 RAs, lixisenatide or exenatide, or long-acting GLP-1 RAs, exenatide LAR, liraglutide, albiglutide, or dulaglutide (N = 1112

New data is shedding light on a potential link between GLP-1 receptor agonists and long-term vision outcomes, with findings suggesting these therapies may be associated with a lower risk of legal blindness in patients with type 2 diabetes